US BioTek Laboratories

US BioTek operates three core testing divisions: environmental and respiratory allergy profiles, food sensitivity panels (primarily IgG-mediated), and mycotoxin/toxicology assays. The lab uses ELISA immunology arrays for antibody detection, LC-MS/MS for quantitative toxicology, and PCR for molecular diagnostics. These panels are targeted toward functional and integrative medicine practitioners who use them as clinical decision-support tools.

No. US BioTek remains an independently held laboratory, per Washington State business records. This independent structure differentiates it from the majority of mid-sized reference labs, which have been acquired by private equity platforms or integrated into hospital-run laboratory outreach programs over the past decade.

No. US BioTek is an operating clinical laboratory business, not a family office or investment vehicle. Its presence in an allocation database likely reflects a data categorization error. The firm generates revenue from patient testing services, not from managing assets or deploying capital into external investments.

US BioTek accepts physician-ordered specimens from all 50 United States. The lab's logistics network relies on overnight courier partnerships to transport ambient and frozen specimens from practitioner offices to its single processing facility in Shoreline, Washington.

Unlike standard IgE-mediated allergy testing, which detects immediate hypersensitivity, US BioTek's food sensitivity panels measure IgG antibody responses, per its published test methodology. These delayed-reaction panels are clinically utilized in functional medicine to guide elimination diets and dietary modification protocols, though their clinical utility remains a subject of debate in mainstream allergy and immunology societies.